Characterization of N-ethyl-N-nitrosourea-induced malignant and benign breast tumors in rats by using three MR contrast agents

Journal of Magnetic Resonance Imaging

Volumn 9, Issue 2, 1999, Pages 177-186

  Su, Min Ying ^a   Wang, Zhiheng ^a   Carpenter, Philip M ^a   Lao, Xiaoyan ^a   Mühler, Andreas ^b   Nalcioglu, Orhan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

Dynamic contrast enhanced MRI; Malignant and benign breast tumors; MR contrast agents; Pharmacokinetic analysis

Indexed keywords

DENDRIMER; ETHYLNITROSOUREA; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE ALBUMIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; BREAST TUMOR; CANCER GRADING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED CANCER; INTRADUCTAL CARCINOMA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MACROMOLECULE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO;

ALBUMINS; ANIMALS; CARCINOGENS; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; ETHYLNITROSOUREA; FEMALE; GADOLINIUM; GADOLINIUM DTPA; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0033007860     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199902)9:2<177::AID-JMRI5>3.0.CO;2-8     Document Type: Article

References (35)

1. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989;170:681-686.
2. Gribbestad IS, Nilsen G, Fjosne H, et al. Contrast-enhanced magnetic resonance imaging of the breast. Acta Oncol 1992;31:833-842.
3. Flickinger FW, Allison JD, Sherry RM, Wright JC. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 1993;11:617-620.
4. Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994;190:485-493.
5. Heywang-Kobrunner SH. Contrast-enhanced magnetic resonance imaging of the breast. Invest Radiol 1994;29:94-104.
6. Kelcz F, Santyr G. Gadolinium-enhanced breast MRI. Crit Rev Diagn Imaging 1995;36:287-338.
7. Heywang-Kobrunner SH, Viehweg P, Heinig A, Kuchler C. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol 1997;24:94-108.
8. Mussurakis S, Buckley DL, Drew PJ, et al. Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumours. Clin Radiol 1997;52:516-526.
9. den Boer JA, Hoenderop RK, Smink J, et al. Pharmacokinetic analysis of Gd-DTPA enhancement in dynamic three-dimensional MRI of breast lesions. J Magn Reson Imaging 1997;7:702-715.
10. Heywang-Kobrunner SH, Schlegel A, Beck R, et al. Contrast-enhanced MRI of the breast after limited surgery and radiation therapy. J Comput Assist Tomogr 1993;17:891-900.
11. Whitehouse GH, Moore NR. MR imaging of the breast after surgery for breast cancer. Magn Reson Imaging Clin North Am 1994;2:591-603.
12. Mussurakis S, Buckley DL, Bowsley SJ, et al. Dynamic contrast-enhanced magnetic resonance imaging of the breast combined with pharmacokinetic analysis of gadolinium-DTPA uptake in the diagnosis of local recurrence of early stage breast carcinoma. Invest Radiol 1995;30:650-662.
13. Murray AD, Redpath TW, Needham G, Gilbert FJ, Brookes JA, Eremin O. Dynamic magnetic resonance mammography of both breasts following local excision and radiotherapy for breast carcinoma. Br J Radiol 1996;69:594-600.
14. Rieber A, Merkle E, Zeitler H, et al. Value of MR mammography in the detection and exclusion of recurrent breast carcinoma. J Comput Assist Tomogr 1997;21:780-784.
15. Jain RK. Transport of molecules across tumor vasculature. Cancer Metast Rev 1987;6:559-593.
16. Dvorak HF. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. In: Effects of therapy on biology and kinetics of the residual tumor, Part A: pre-clinical aspects. New York: Wiley-Liss Inc.; 1990. p 317-330.
17. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
18. Adam G, Muhler A, Spuntrup E, et al. Differentiation of spontaneous canine breast tumors using dynamic magnetic resonance imaging with 24-gadolinium-DTPA-cascade-polymer, a new blood-pool agent. Preliminary experience. Invest Radiol 1996;31:267-274.
19. Su MY, Mühler A, Lao X, Nalcioglu O. Tumor characterization with dynamic contrast enhanced MRI using MR contrast agents of various molecular weights. Magn Reson Med 1998;39:259-269.
20. Su MY, Jao JC, Nalcioglu O. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: studies in rat muscle Magn Reson Med 1994;32:714-724.
21. Stoica G, Koestner A, Capen CC. Neoplasms induced with high single doses of N-ethyl-N-nitrosourea in 30-day-old Sprague-Dawley rats, with special emphasis on mammary neoplasia. Anticancer Res 1984;4:5-12.
22. Werner EA. The constitution of carbamides. Part IX, The interaction of nitroso acid and mono-substituted ureas. J Chem Soc 1919;115: 1093.
23. Su MY, Najafi AA, Nalcioglu O. Regional comparison of tumor vascularity and permeability parameters measured by albumin-Gd-DTPAand Gd-DTPA. Magn Reson Med 1995;34:402-411.
24. Russo J, Russo IH, Rogers AE, van Zwieten MJ, and Gusterson B. Tumour of the mammary gland in US. In: Turusov VS, Mohr U, editors. Pathology of tumours in laboratory animals. Vol 1. Tumours of the rat. Lyon, France: International Agency for Research on Cancer; 1990. p 47-78.
25. Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 1994;102(suppl 1):S3-S8.
26. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
27. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA In patients with multiple sclerosis and brain tumors. Magn Reson Med 1990;16:117-131.
28. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357-367.
29. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-628.
30. Shames DM, Kuwatsuru R, Vexler V, Muhler A, Brasch RC. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 1993;29:616-622.
31. Hochman MG, Orel SG, Powell CM, Schnall MD, Reynolds CA, White LN. Fibroadenomas: MR imaging appearances with radiologic-histopathologic correlation. Radiology 1997;204:123-129.
32. Baxter LT, Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3030-3051.
33. Su MY, Lao X, Nalcioglu O. Quantitative comparison of pharmacokinetics of polylysine-Gd-DTPA, Gd-DTPA-24-cascade-polymer, and Gd-DTPA in blood, liver, and tumor of rats. In: Proceedings of the 4th SMR Annual Meeting, New York, 1996. p 1697.
34. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metast Rev 1996;15:165-176.
35. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatr Radiol 1998;28:67-78.